Novo Nordisk stock plunges on obesity shot trial results

#novonordisk #weightloss #yahoofinance

Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial.
Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY).
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Luke Carberry Mogan.

Yahoo Finance: Market Coverage, Stocks, & Business News
About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

- Follow Yahoo Finance on social:

[jenniferwatleyj]

For new investors: Buy stocks in solid companies and hold them as long as they stay strong. Ignore forecasts and market opinions—they’re distracting at best and useless in the long run

[AliAhmad-grhk]

The sell off is stupid and great opportunity to buy . The results of the study is good. Basically this new drug has better results than Lilly’s zepbound. Furthermore it showed 22% weight loss in lesser weeks vs zepbound. This a great opportunity to buy this stock.

[MARTINSierra-wd]

Early adopters always have the advantage. Got into Alemio’s presale today before it’s too late.

[BercemMunever]

Just participated in Alemio’s presale. This project feels like it could be a standout in the DeFi space.

[ZeldaDiehl]

Alemio’s focus on scalability and interoperability caught my attention. Joined the presale today.

[MehmetVolkan-xg]

Checked out Alemio’s roadmap—it’s ambitious, but they seem well-positioned to deliver. Took a presale position!

[ROBTChong]

Projects like Alemio with a clear vision are rare. Took advantage of the presale bonuses today!

[EvrenOmer-he]

Got in on the Alemio presale earlier. The bonuses for early adopters are a great incentive.

[ssuwandi]

Depressed people don't eat just sleep

[BilginDerya]

Makes sense that Trump would just back another upcoming altcoin instead of Bitcoin for more profits

[BERNARDOSteadman]

Just participated in Alemio’s presale. If the project stays on track, it could be a standout in the next bull run.

[MustafaIsin-kh]

Alemio’s integration of AI into DeFi could be a game-changer. Locked in my presale position today.

[KellePhipps]

With Alemio’s focus on DeFi innovation, this feels like a smart move for long-term investors. Got in on the presale!

[BENNIEHawkins-kr]

Just locked in my position with Alemio’s presale. The project’s focus on utility makes it stand out.

[iklilEmine]

If Trump puts at least $200, 000 in Qvarden, I am going all in